- Home
- YSWY vs MNKD Comparison
YSWY vs MNKD Comparison
Compare YSWY & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YSWY | MNKD |
|---|---|---|
| Founded | 2015 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2021 | 2004 |
Fundamental Metrics
Financial Performance| Metric | YSWY | MNKD |
|---|---|---|
| Price | $20.74 | $3.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $29.63 | $7.84 |
| AVG Volume (30 Days) | 296.2K | ★ 4.6M |
| Earning Date | 11-15-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | $22.99 | $26.86 |
| Revenue Next Year | N/A | $13.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $18.92 | $2.23 |
| 52 Week High | $26.34 | $6.51 |
Technical Indicators
Market Signals| Indicator | YSWY | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 46.68 | 37.41 |
| Support Level | $20.06 | $3.24 |
| Resistance Level | $21.42 | $4.23 |
| Average True Range (ATR) | 0.75 | 0.22 |
| MACD | 0.17 | -0.01 |
| Stochastic Oscillator | 77.30 | 11.85 |
Price Performance
Historical ComparisonAbout MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.